Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
Kevin J. Harrington, Robert L. Ferris, George Blumenschein, A. Dimitrios Colevas, Jérôme Fayette, Lisa Licitra, Stefan Kasper, Caroline Even, Everett E. Vokes, Francis Worden, Nabil F. Saba, Naomi Kiyota, Robert Haddad, Makoto Tahara, Viktor Grünwald, James W. Shaw, Manish Monga, Mark Lynch, Fiona Taylor, Michael DeRosaLaura Morrissey, Kim Cocks, Maura L. Gillison, Joël Guigay
Dive into the research topics of 'Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial'. Together they form a unique fingerprint.